2.415USD-4.92%Mkt Cap: 309.44M USDP/E: —Last update: 2026-05-26
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops N…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap309.44M USD
Enterprise Value255.78M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-59.00M USD
Revenue/Share—
Last Price2.415 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees127
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.43
PEG—
EV/EBITDA-4.09
EV/Revenue—
P/S—
P/B2.24
EPS (TTM)-0.46
EPS (Forward)-0.74
52W Range
0.620049% of range4.310
52W High4.310 USD
52W Low0.6200 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-37.59%
ROA-30.87%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-50.70M USD
CapEx (TTM)1.28M USD
FCF Margin—
FCF Yield-9.33%
Net Debt-67.00M USD
Net Debt/EBITDA1.07
Balance Sheet
Debt/Equity0.19
Current Ratio11.85
Quick Ratio11.49
Book Value/Sh1.136 USD
Cash/Share0.7540 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)4.000 USD
Target Range4.000 USD – 4.000 USD
# Analysts1
Ownership
Shares Out.127.08M
Float47.22M
Insiders33.21%
Institutions47.40%
Short Interest
Short Ratio2.3d
Short % Float1.15%
Short % Out.0.56%
Shares Short715.64K
Short (prev mo.)674.95K
Technical
SMA 502.933 (-17.7%)
SMA 2001.926 (+25.4%)
Beta0.75
S&P 52W Chg28.31%
Avg Vol (30d)352.16K
Avg Vol (10d)488.23K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—